GU Cancers 2021 | 18F-DCFPyL PET/CT imaging up-stages patients with prostate cancer

Frédéric Pouliot, MD, PhD, FRCSC, University Hospital of Quebec and Laval University, Quebec, Canada, outlines the results of the Phase II/III OSPREY trial (NCT02981368) investigating the prostate-specific membrane antigen (PSMA)-targeted agent, 18F-DCFPyL, with PET/CT imaging in patients with prostate cancer. Cohort A treated patients with newly-diagnosed prostate cancer and cohort B treated patients with recurrent or metastatic prostate cancer. 18F-DCFPyL PET/CT imaging upstaged 58% of patients from M0 to M1, of whom 91% who underwent extra-pelvic biopsy were confirmed to have M1 disease by pathology. This interview took place during the 2021 Genitourinary Cancers Symposium.